InnovAge (INNV) Q3 2025 earnings summary

Executive summary

• Third quarter revenue grew 13% year-over-year to $218.1 million, with census up 10% to approximately 7,530 participants, and operations reflecting disciplined cost management and transformation initiatives.

• Net loss widened to $11.1 million from $6.2 million year-over-year, impacted by higher costs and a $10.7 million accrual for an anticipated stockholder lawsuit settlement.

• Adjusted EBITDA rose to $10.8 million (4.9% margin), more than tripling year-over-year, driven by operational efficiency and cost discipline.

• Transformation efforts and investments in compliance, technology, and pharmacy integration are underway, supporting scalability and quality.

• Chief Medical Officer transition plan in place following departure.

Financial highlights

• Revenue: $218.1 million, up 13% year-over-year and 4.4% sequentially.

• Adjusted EBITDA: $10.8 million (4.9% margin), up from $3 million (1.5%) year-over-year.

• Net loss: $11.1 million, compared to $6.2 million loss in prior year quarter.

• Center-level contribution margin: $40.7 million (18.7% of revenue), up 100 basis points sequentially.

• Cash and equivalents: $60.5 million; short-term investments: $41.3 million; total debt: $77.3 million.

Outlook and guidance

• Fiscal 2025 guidance reaffirmed: census 7,300–7,750; member months 86,000–89,000; revenue $815–$865 million; adjusted EBITDA $24–$31 million.

• De novo center losses projected at $18–$20 million for fiscal 2025.

• Guidance remains conservative due to risk score true-up variability and macroeconomic risks.